Education
About Us
Working with TipRanks
Follow Us
Achilles Therapeutics (ACHL)
NASDAQ:ACHL
Top Page
Achilles Therapeutics
(NASDAQ:ACHL)
50Neutral
Achilles Therapeutics (ACHL) vs. S&P 500 (SPY)
Market Cap
$60.83M
Dividend YieldN/A
Average Volume (3M)1.84M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees204
SectorHealthcare
Sector Strength66
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,088,000
10 Day Avg. Volume1,029,946
30 Day Avg. Volume1,836,713
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Achilles Therapeutics Business Overview & Revenue Model
Company DescriptionAchilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyAchilles Therapeutics generates revenue primarily through the development and commercialization of its T cell therapies. The company aims to bring its therapeutic products to market by advancing them through clinical trials and obtaining regulatory approvals. Revenue streams may include licensing agreements, collaboration partnerships with larger pharmaceutical companies, and potential milestone payments or royalties from successful commercialization of its therapies. Additionally, Achilles Therapeutics may engage in research and development collaborations that provide funding and resources in exchange for access to its proprietary technology platform. These collaborations and partnerships are significant contributors to its earnings, helping to finance further research and development activities.
Achilles Therapeutics Financial Statement Overview
Summary
Achilles Therapeutics faces typical pre-commercial biotech challenges, with zero revenue and widening net losses. The balance sheet shows stability in equity with low debt, but declining assets and equity reflect strain. Negative cash flows highlight the need for further financing.Income Statement
Achilles Therapeutics has consistently reported zero revenue over the past years, indicating a lack of commercialized products. The company shows a widening net loss, with a significant negative net profit margin. Despite improvements in EBITDA margin, the overall income statement reflects financial challenges typical in biotech firms pre-commercialization.20
Very Negative
Balance Sheet
The balance sheet reveals a stable equity position with a low debt-to-equity ratio, suggesting conservative financial leverage. However, the declining stockholders' equity and total assets over the years reflect financial strain. The equity ratio remains strong, indicative of shareholder investment stability despite ongoing losses.45
Neutral
Cash Flow
Achilles Therapeutics has negative operating and free cash flows, which are common in pre-revenue biotech companies. The free cash flow growth rate suggests further cash burn, while the operating cash flow to net income ratio indicates significant cash outflows relative to earnings, reflecting the need for continued financing to sustain operations.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -4.71M | -4.73M | -3.69M | -3.29M | -778.00K | -303.25K | EBIT |
| -70.87M | -75.25M | -78.38M | -64.19M | -33.73M | -13.78M | EBITDA |
| -65.90M | -70.44M | -78.38M | -57.77M | -32.95M | -13.47M | Net Income Common Stockholders |
| -64.12M | -69.67M | -71.18M | -61.10M | -33.20M | -13.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 97.86M | 131.54M | 173.34M | 266.32M | 177.85M | 97.59M | Total Assets |
| 105.20M | 161.46M | 220.36M | 317.11M | 218.92M | 105.20M | Total Debt |
| 4.00M | 4.62M | 8.58M | 12.26M | 15.98M | 487.00K | Net Debt |
| -93.60M | -126.92M | -164.76M | -254.06M | -161.87M | -97.11M | Total Liabilities |
| 3.86M | 19.09M | 23.31M | 27.58M | 29.55M | 3.86M | Stockholders Equity |
| 101.35M | 142.37M | 197.04M | 289.53M | 189.37M | 101.35M |
| Cash Flow | Free Cash Flow | ||||
| -31.47M | -49.55M | -67.05M | -66.92M | -37.10M | -15.08M | Operating Cash Flow |
| -30.66M | -48.45M | -59.53M | -59.28M | -25.25M | -14.14M | Investing Cash Flow |
| -837.59K | -1.10M | -7.51M | -7.63M | -11.85M | -942.00K | Financing Cash Flow |
| ― | 9.00K | 1.00K | 160.75K | 113.70M | 93.62M |
Achilles Therapeutics Technical Analysis
Positive
1.48
Price Trends
1.33
Positive
1.20
Positive
1.03
Positive
Market Momentum
0.04
Negative
74.97
Negative
75.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACHL, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.33, and above the 200-day MA of 1.03, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 74.97 is Negative, neither overbought nor oversold. The STOCH value of 75.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACHL.
Achilles Therapeutics Risk Analysis
Achilles Therapeutics disclosed 1 risk factors in its most recent earnings report. Achilles Therapeutics reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Achilles Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $60.83M | ― | -52.41% | ― | ― | ― | |
49 Neutral | $6.88B | 0.82 | -52.97% | 2.48% | 20.92% | 1.17% | |
48 Neutral | $1.13B | ― | -57.48% | ― | 13698.99% | 31.46% | |
46 Neutral | $58.88M | ― | -273.36% | ― | 194.23% | 45.50% | |
42 Neutral | $103.45M | ― | -54.21% | ― | -78.55% | -0.92% | |
42 Neutral | $540.68M | ― | -17.48% | ― | ― | ― | |
40 Underperform | $47.13M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
ACHL
Achilles Therapeutics
1.48
0.23
18.40%
FATE
Fate Therapeutics
0.88
-6.46
-88.01%
KPTI
Karyopharm Therapeutics
4.35
-18.30
-80.79%
IOVA
Iovance Biotherapeutics
3.63
-11.19
-75.51%
ADAP
Adaptimmune Therapeutics
0.22
-1.36
-86.08%
IMTX
Immatics
4.71
-5.80
-55.19%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.